QC6352

Researchers report that DHODH, an enzyme involved in pyrimidine synthesis, is the key target through which the KDM4 inhibitor QC6352 acts against glioblastoma stem cells. The finding, published in Nature, suggests the compound's anti-cancer effect works via metabolic disruption rather than its intended epigenetic pathway, with implications for treating this aggressive brain cancer.